# Cibotercept

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/cibotercept
Canonical HTML page: https://gethealthbrief.com/entity/cibotercept

## Timeline

- **2026-03-04**: FY 2025 Earnings — Released full-year financial results and updated 2026 clinical guidance.
- **2026**: Anticipated Data — Expected top-line data readouts for multiple Phase 2 programs.
- **2025-Q3**: Cibotercept Progress — Initiated additional cohorts in PAH studies to evaluate dose-response.
- **2025-Q1**: Trial Expansion — Keros expanded the TROPOS trial to include broader MDS patient populations.

## Recent coverage (1 stories)

### Keros Therapeutics Advances TGF-β Pipeline Amid Q4 2025 Financial Results
2026-03-04 23:37:29 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Keros Therapeutics reported its full-year 2025 results, highlighting significant clinical progress in its TGF-β protein superfamily pipeline for hematologic and cardiovascular disorders. The company maintains a robust cash position to fund pivotal trials for elritercept and cibotercept through key upcoming data readouts in 2026.
Full story: https://gethealthbrief.com/story/keros-therapeutics-q4-2025-financial-results-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.